DOSSIER · 13F-HR · Q2 2026

BML Capital Management, LLC

$176M in tracked AUM across 18 positions as of Q2 2026.

BC
CIK 0001616824 · last filed Jun 30, 2026
Total AUM
$176M
as of Q2 2026
Holdings
18
positions
Whale Score
71
71
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026
Portfolio Overview

BML Capital Management, LLC manages a concentrated, high-conviction portfolio totaling approximately $101.6 million as of the reporting period ended September 30, 2025. The firm employs a focused investment strategy, holding only 15 securities, which indicates a preference for selectivity over broad diversification. The portfolio experienced a significant contraction of 23.1% in total value, declining from $132.18 million in the previous quarter. This reduction in asset va...

Key Holdings

The portfolio is characterized by a high level of concentration in its top tier names. The three largest positions—Aclaris Therapeutics Inc (ACRS), Atea Pharmaceuticals Inc (AVIR), and Adverum Biotechnologies Inc (ADVM)—collectively represent 61.61% of the total portfolio value.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
ACRS
ACLARIS THERAPEUTICS INC
$63M12.0M36.0%
02
AVIR
ATEA PHARMACEUTICALS INC
$32M7.0M18.4%
03
ENGN
ENGENE THERAPEUTICS INC
$12M6.7M6.6%
04
KHC
KRAFT HEINZ CO
$11M465K6.2%
05
OM
OUTSET MED INC
$11M2.5M6.2%
06
KMX
CARMAX INC
$9M173K5.2%
07
TLYS
TILLYS INC
$9M2.1M5.1%
08
PMVP
PMV PHARMACEUTICALS INC
$7M5.3M4.1%
09
TIL
INSTIL BIO INC
$5M646K2.8%
10
TGT
TARGET CORP
$5M38K2.8%

Filing history

2026Q2Jun 30
$176M 13.0%
18 positionsView →
2026Q1Mar 31
$156M 34.6%
16 positionsView →
2025Q4Dec 31
$116M 13.9%
16 positionsView →
2025Q3Sep 30
$102M 23.1%
15 positionsView →
2025Q2Jun 30
$132M 17.8%
24 positionsLocked
2025Q1Mar 31
$112M 30.3%
21 positionsLocked
2024Q4Dec 31
$161M 5.3%
25 positionsLocked
2024Q3Sep 30
$170M 21.3%
29 positionsLocked
2024Q2Jun 30
$140M 7.6%
28 positionsLocked
2024Q1Mar 31
$152M 14.9%
32 positionsLocked
2023Q4Dec 31
$132M 21.2%
35 positionsLocked
2023Q3Sep 30
$109M 2.0%
26 positionsLocked
Showing 12 of 15